Ipamorelin Reconstitution Calculator

Ipamorelin is a synthetic pentapeptide that works as a selective growth hormone secretagogue, binding the ghrelin receptor (GHS-R1a) in the pituitary to trigger short, natural-style pulses of growth hormone. It was originally developed by Novo Nordisk and is one of the most receptor-selective GHRPs, which is why it circulates as a research peptide rather than an approved medicine. It contains no growth hormone itself — it prompts your own pituitary to release more.

In research and clinical write-ups, ipamorelin is discussed in micrograms — commonly around 100–300 mcg per dose, subcutaneously, once or up to a few times a day. Because its half-life is only about 2 hours, doses are usually timed to an empty stomach and often before bed, when natural GH release peaks. These figures are not an approved schedule; the right amount, frequency, and whether it's appropriate at all are clinical decisions.

Add bacteriostatic water to the dry vial and let it dissolve without shaking. For example, a 5 mg vial + 2 mL of water gives 2.5 mg/mL (2,500 mcg/mL); a 250 mcg dose is then 0.1 mL, which is 10 units on a U-100 insulin syringe. Adjust the math to your vial's actual strength — the calculator above handles any vial size and target dose. Working in micrograms matters here, since ipamorelin doses are far smaller than the milligram doses used for GLP-1 peptides.

Ipamorelin's defining trait is selectivity: unlike older secretagogues such as GHRP-6, it raises growth hormone with little effect on cortisol, prolactin, or strong hunger signaling, so appetite spikes tend to be mild or absent. It does not directly raise testosterone — it acts on the GH/IGF-1 axis, not the reproductive hormone axis. This "clean" profile is exactly why it's the ghrelin-receptor half so often paired with a separate GHRH-type peptide that works through a different receptor; how any such pairing is dosed is a clinical decision, not something to merge on a calculator.

Despite ipamorelin's online reputation as the "safest" or "cleanest" peptide, that reputation rests mostly on short Phase II trials and anecdote — it has never been approved by the FDA or any major regulator and has limited long-term human safety data. Reported effects include injection-site reactions, headache, and water retention, and any sustained rise in GH/IGF-1 can affect blood sugar and insulin sensitivity, so it is not risk-free. Store lyophilized vials refrigerated and out of light; once reconstituted, keep them cold and use within a few weeks. Selectivity reduces certain side effects — it does not make an unapproved compound proven-safe.